NCT05343013View on ClinicalTrials.gov

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

May 15, 2027

Study Completion Date

May 15, 2027

Conditions

Colorectal Cancer

Interventions

DRUG

TAS-102

GIven by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Taiho

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER